Çѱ¹À¯¹æ¾ÏÇÐȸ 2023 School of Breast Disease (Day 1) : 2023-08-26
±³À°ÀÏÀÚ : 2023-08-26
±³À°Àå¼Ò : ÇÁ·¹Áö´øÆ® È£ÅÚ 31Ãþ ¸ð©ƮȦ
±³À°ÁÖÁ¦ : 2023 School of Breast Disease (Day 1)
ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö
¿¬¶ôó : 02-3461-6060
À̸ÞÀÏ : kbcs@kbcs.or.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú
Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í "°ÀÇ Module 200,000¿ø
Hands-on Module 200,000¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 08:55~09:20 Mammography and ultrasonography °ºÀÁÖ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 09:20~09:45 MRI and other breast imaging tool Á¶³ª¸®¾ß(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 09:45~10:10 Essence of breast pathology ¾ÈÁ¤¼®(°í´ë¾È¾Ïº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 10:10~10:35 Breast cancer staging & biomarker ÀÌÀåÈñ(µ¿Åº¼º½Éº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 10:35~11:00 Management of benign breast disease ±èÀÇÅÂ(´Ü±¹´ëº´¿ø)
ÈÞ½Ä 08¿ù 26ÀÏ 11:00~11:10 Coffee break ()
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 11:10~11:35 Breast surgery °í¹ü¼®(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 11:35~12:00 Axillary surgery À¯Àç¹Î(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 12:00~12:25 Endoscopic & robotic breast surgery ÃÖÈñÁØ(»ï¼ºÃ¢¿øº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 12:25~12:50 Adjuvant radiation therapy after breast conserving therapy Á¶¿¬¾Æ(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 12:50~13:15 Postmastectomy radiotherapy and radiotherapy in metastatic breast cancer ±è¼ö»ê(¼¿ï¾Æ»êº´¿ø)
½Ä»ç 08¿ù 26ÀÏ 13:15~14:00 Lunch ()
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 14:00~14:30 Adjuvant/neoadjuvant chemotherapy, immunotherapy, and PARP inhibitors ±è¹Îȯ(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 14:30~15:00 Adjuvant/neoadjuvant endocrine therapy and CDK4/6 inhibitor therapy ¹è¼þÁØ(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 15:00~15:30 Adjuvant/neoadjuvant HER2-targeted therapy ÀÌÀÎÈñ(Ä¥°î°æºÏ´ëº´¿ø)
ÈÞ½Ä 08¿ù 26ÀÏ 15:30~15:50 Coffee break ()
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 15:50~16:20 Triple-negative breast cancer ±è½½±â(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 16:20~16:50 HER2-positive breast cancer Á¤ÀçÈ£(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 08¿ù 26ÀÏ ¸ð©ƮȦ 16:50~17:20 Estrogen-dependent metastatic breast cancer ½Å°©¼ö(¼¿ï¼º¸ðº´¿ø)